Pakistan Pharma calls for drug price hikes

6 July 2008

The Pakistani government should allow drug producers to make upward revision in the prices of their products ranging from 15% to 20% to sustain the sector's existence, according to Pakistan Pharmaceutical Manufacturers Association chairman Kashif Sajjad Sheikh who, at a press conference in Karachi, also warned of a severe shortage of medicines including life saving drugs in the country unless "something was done."

In an interview, he added that, "during the last seven years, prices of medicines remained unchanged despite a steep rise in inflation and increase in the input of the pharmaceutical sector, which has forced the industry to face its worst crises ever."

Currently, he noted, there are 400 pharmaceutical companies, 375 local and 25 international, operating in the country supplying 75% of the medical requirements of the population and providing employment opportunities to at least 450,000 people.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight